HDL and cardiovascular disease

Stephen J Nicholls; Adam J Nelson

doi:10.1016/j.pathol.2018.10.017

HDL and cardiovascular disease

Pathology. 2019 Feb;51(2):142-147. doi: 10.1016/j.pathol.2018.10.017. Epub 2019 Jan 3.

Authors

Stephen J Nicholls¹, Adam J Nelson²

Affiliations

¹ South Australian Health and Medical Research Institute, Adelaide, SA, Australia; Monash University, Adelaide, SA, Australia. Electronic address: stephen.nicholls@sahmri.com.
² South Australian Health and Medical Research Institute, Adelaide, SA, Australia.

PMID: 30612759
DOI: 10.1016/j.pathol.2018.10.017

Abstract

High-density lipoprotein (HDL) has received increasing interest due to observations of an inverse relationship between its systemic levels and cardiovascular risk and targeted interventions in animal models that have had favourable effects on atherosclerotic plaque. In addition to its pivotal role in reverse cholesterol transport, HDL has been reported to possess a range of functional properties, which may exert a protective influence on inflammation, oxidation, angiogenesis and glucose homeostasis. This has led to the development of a range of HDL targeted therapeutics, which have undergone evaluation in clinical trials. The current state of HDL in cardiovascular prevention will be reviewed.

Keywords: HDL; atherosclerosis; cardiovascular risk; clinical trials; lipids.

Publication types

Review

MeSH terms

Atherosclerosis / prevention & control
Cardiovascular Diseases / prevention & control*
Humans
Inflammation
Lipoproteins, HDL / blood*
Risk

Substances

Lipoproteins, HDL